Slow and steady? Strategic adjustments in response caution are moderately reliable and correlate across tasks.

Speed-accuracy trade-offs are often considered a confound in speeded choice tasks, but individual differences in strategy have been linked to personality and brain structure. We ask whether strategic adjustments in response caution are reliable, and whether they correlate across tasks and with impulsivity traits. In Study 1, participants performed Eriksen flanker and Stroop tasks in two sessions four weeks apart. We manipulated response caution by emphasising speed or accuracy. We fit the diffusion model for conflict tasks and correlated the change in boundary (accuracy – speed) across session and task. We observed moderate test-retest reliability, and medium to large correlations across tasks. We replicated this between-task correlation in Study 2 using flanker and perceptual decision tasks. We found no consistent correlations with impulsivity. Though moderate reliability poses a challenge for researchers interested in stable traits, consistent correlation between tasks indicates there are meaningful individual differences in the speed-accuracy trade-off

Low and variable correlation between reaction time costs and accuracy costs explained by accumulation models: Meta-analysis and simulations.

The underpinning assumption of much research on cognitive individual differences (or group differences) is that task performance indexes cognitive ability in that domain. In many tasks performance is measured by differences (costs) between conditions, which are widely assumed to index a psychological process of interest rather than extraneous factors such as speed–accuracy trade-offs (e.g., Stroop, implicit association task, lexical decision, antisaccade, Simon, Navon, flanker, and task switching). Relatedly, reaction time (RT) costs or error costs are interpreted similarly and used interchangeably in the literature. All of this assumes a strong correlation between RT-costs and error-costs from the same psychological effect. We conducted a meta-analysis to test this, with 114 effects across a range of well-known tasks. Counterintuitively, we found a general pattern of weak, and often no, association between RT and error costs (mean r = .17, range −.45 to .78). This general problem is accounted for by the theoretical framework of evidence accumulation models, which capture individual differences in (at least) 2 distinct ways. Differences affecting accumulation rate produce positive correlation. But this is cancelled out if individuals also differ in response threshold, which produces negative correlations. In the models, subtractions between conditions do not isolate processing costs from caution. To demonstrate the explanatory power of synthesizing the traditional subtraction method within a broader decision model framework, we confirm 2 predictions with new data. Thus, using error costs or RT costs is more than a pragmatic choice; the decision carries theoretical consequence that can be understood through the accumulation model framework

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1-2 (89%). Five patients experienced grade 3-4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments

Intra-individual reaction time variability in amnestic mild cognitive impairment: a precursor to dementia?

We used an exogenous target detection cueing paradigm to examine whether intra-individual reaction time variability (IIV) or phasic alerting varied significantly between patients with amnestic mild cognitive impairment (aMCI) (n = 45) and healthy older adult controls (n = 31) or between those with aMCI who, within a 2.5 year follow-up period, developed dementia (n = 13) and those who did not (n = 26). Neither IIV, nor simple reaction time, differentiated aMCI from healthy aging, indicating that raised IIV and overall response slowing are not general characteristics of aMCI. However, within the aMCI group, IIV did differentiate between those who converted to dementia and those who remained with a diagnosis of aMCI (non-converters), being significantly more variable in those who later developed dementia. Furthermore, there was no difference in IIV between non-converters and healthy controls. High IIV appears related to an increased probability that an individual with aMCI will become demented within 2.5 years, rather than to amnestic dysfunction per se. In contrast, phasic alerting performance significantly differentiated aMCI from healthy aging, but failed to discriminate those with aMCI who developed dementia from those who did not. In addition, those patients with aMCI who did not develop dementia still showed a significantly poorer phasic alerting effect compared to healthy aging. The phasic alerting abnormality in aMCI compared to healthy aging does not appear specifically related to the performance of those patients for whom aMCI represents the prodromal stages of dementia